| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 10/19/2004 | US6806086 Causative agent of the mystery swine disease, vaccine compositions and diagnostic kits |
| 10/19/2004 | US6806079 Methods for producing members of specific binding pairs |
| 10/19/2004 | US6806061 G protein-coupled receptor gene and methods of use therefor |
| 10/19/2004 | US6806059 Nucleotide sequences coding enzymatic polypeptide for use innthe treatment of asthma, and for use in laundry detergent and stain removers |
| 10/19/2004 | US6806058 Comprises biotinylated matrix which binds isotypic regions of immunoglobulins/antibodies; for improving the resolution of detection of multiple proteins and/or cell surface markers |
| 10/19/2004 | US6806055 Preparing viral vaccine; obtain glycoprotein, determine neutralizing epitope, generate vaccine associated with neutralizing epitope |
| 10/19/2004 | US6805869 Cellular vaccines and immunotherapeutics and methods for their preparation |
| 10/19/2004 | US6805868 Isolated, recombinant polypeptide comprising member selected from specified amino acid sequence and immunogenic fragment of at least 15 contiguous amino acids of that sequence; induces antibody or t-cell mediated immune response when administered |
| 10/19/2004 | US6805865 Compositions and methods for treating cancer and hyperproliferative disorders |
| 10/19/2004 | US6805864 Type I angiotensin II receptor specific monoclonal antibodies and hybridomas |
| 10/19/2004 | US6805863 Comprises antibodies/proteins providing inhibition of prothrombinase; treatment and prevention of bacterial and viral infections, allograft/xenograft rejection, glomerulo-nephritis, cancer, gastrointestinal diseases, and fetal loss |
| 10/19/2004 | US6805862 Generating in subject immune response against ganglioside gd3 by administering antiidiotypic antibody bec-2 (atcc no. hb 10153) |
| 10/19/2004 | CA2323096C Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| 10/14/2004 | WO2004088326A2 Gastrin hormone immunoassays |
| 10/14/2004 | WO2004087921A1 Human solid cancer antigen peptides, polynucleotides encoding the same and utilization thererof |
| 10/14/2004 | WO2004087915A1 Seb modification and preventive/remedy for diseases with immune abnormality contianing the same |
| 10/14/2004 | WO2004087914A1 Method of constructing antibody |
| 10/14/2004 | WO2004087911A1 Method of constructing hybridoma producing antigen-specific antibody using single antigen-specific b lymphocyte and method of producing monoclonal antibody |
| 10/14/2004 | WO2004087887A2 Intracellular complexes as biomarkers |
| 10/14/2004 | WO2004087876A2 Use of red blood cells to facilitate cell activation |
| 10/14/2004 | WO2004087764A1 Recombinant antibody recognizing dioxin and gene encoding the antibody |
| 10/14/2004 | WO2004087763A1 Modified antibody against cd22 and utilization thereof |
| 10/14/2004 | WO2004087762A1 Antibodies inhibiting tansportation activity of peptide transporter |
| 10/14/2004 | WO2004087761A1 Purification of human monoclonal antibody and human polyclonal antibody |
| 10/14/2004 | WO2004087760A1 Antibodies directed against hepatitis c virus e1e2 complex, compositions of hcv particles, and pharmaceutical compositions |
| 10/14/2004 | WO2004087759A2 Method and compositions for conversion of antibody activity |
| 10/14/2004 | WO2004087758A2 Il 13 receptor alpha 2 antibody and methods of use |
| 10/14/2004 | WO2004087757A2 Antibodies with enhanced ability to immunomodulate cell functions |
| 10/14/2004 | WO2004087756A2 Antibodies against insulin-like growth factor i receptor and uses thereof |
| 10/14/2004 | WO2004087746A2 Staphylococcus epidermidis antigens |
| 10/14/2004 | WO2004087744A2 Composition and method for nerve regeneration |
| 10/14/2004 | WO2004087738A2 Lupus antibodies for passive immunotherapy of hiv/aids |
| 10/14/2004 | WO2004087736A2 Uses of vascular endothelial growth factor and type i collagen inducible protein (vcip) |
| 10/14/2004 | WO2004087735A2 Proteolytic and covalent antibodies |
| 10/14/2004 | WO2004087216A2 Genetic immunization by means of multiple expression structures in order to produce monoclonal antibodies |
| 10/14/2004 | WO2004087210A1 Method of inducing differentiation and proliferating regulatory t cell by anti-cd52 antibody and medicinal composition therefor |
| 10/14/2004 | WO2004087207A2 Method for inducing apoptosis and aneuploidy regression in cancer cells |
| 10/14/2004 | WO2004087205A1 Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof |
| 10/14/2004 | WO2004087200A2 Vaccine and serum for protection of cystic fibrosis patients against pseudomonas aeruginosa |
| 10/14/2004 | WO2004087062A2 Compositions and methods involving respiratory syncytial virus subgroup b strain 9320 |
| 10/14/2004 | WO2004087058A2 Targeted mhc class i alpha3 vaccine delivery systems |
| 10/14/2004 | WO2004087057A2 Methods for inhibition of angiogenesis |
| 10/14/2004 | WO2004087042A2 Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins |
| 10/14/2004 | WO2004087041A2 An antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same |
| 10/14/2004 | WO2004046182A3 Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases |
| 10/14/2004 | WO2004043988A3 Ptprk immunogenic peptide |
| 10/14/2004 | WO2004043376A3 Compositions and methods for treating or preventing pneumococcal infection |
| 10/14/2004 | WO2004041152A3 Antigenic targets of autoimmune sensorineural hearing loss (aisnhl) and development of tests fro diagnosis and management of aisnhl |
| 10/14/2004 | WO2004032831A3 Metalization of microtubules |
| 10/14/2004 | WO2004026102A3 Treatment of schizophrenia |
| 10/14/2004 | WO2004024866A3 Protein purification |
| 10/14/2004 | WO2004024063A3 Compositions and methods for the diagnosis and treatment of tumor |
| 10/14/2004 | WO2004021010A3 Method of diagnosing colon and gastric cancers |
| 10/14/2004 | WO2004019866B1 Compositions and methods for treating cardiovascular disease |
| 10/14/2004 | WO2004016769A3 Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof |
| 10/14/2004 | WO2004016740A3 Humanized rabbit antibodies |
| 10/14/2004 | WO2004009632A3 Method for the production of an immunostimulating mucin (muc1) |
| 10/14/2004 | WO2004007679A3 Dendritic cell pontentiation |
| 10/14/2004 | WO2003104282A3 Glycoprotein vi - fc fusion protein for treating vascular disorders |
| 10/14/2004 | WO2003102132A3 Non-affinity purification of proteins |
| 10/14/2004 | WO2003089620A3 Phospholipases, nucleic acids encoding them and methods for making and using them |
| 10/14/2004 | WO2003065985A3 Uses of mammalian cytokine; related reagents |
| 10/14/2004 | WO2003061595A3 Antibodies against and compositions containing new amphetamine derivatives |
| 10/14/2004 | WO2003031475A8 Antibodies against kdr, their production and uses |
| 10/14/2004 | WO2002030980A8 Use of anti-human integrin alpha d antibodies to treat spinal cord injury |
| 10/14/2004 | WO2001094377A3 Metalloprotease peptide substrates and methods |
| 10/14/2004 | US20040205835 Jak kinases and regulation of cytokine signal transduction |
| 10/14/2004 | US20040204574 TSA305 gene |
| 10/14/2004 | US20040204359 Methods and compositions in treating pain and painful disorders using 16386,15402, 21165, 1423, 636, 12303, 21425, 27410, 38554, 38555, 55063, 57145, 59914, 94921, 16852, 33260, 58573, 30911, 85913, 14303, 16816, 17827 or 32620 |
| 10/14/2004 | US20040204350 Disease- associated protein |
| 10/14/2004 | US20040203157 Transfroming arabidopsis with expression vector coding genes associated with heat, freeze, salt and drought resistance; using ribonucleoproteins to control effivient gene transcription in plants; bioreactors |
| 10/14/2004 | US20040203155 Methods for transfecting T cells |
| 10/14/2004 | US20040203144 Using calcium-activated chloride channels (CLCA) to identify modulators for treatment of bronchitis, asthma, cystic fibrosis, chronic obstructive pulmonary disease (COPD) and bronchiectasis |
| 10/14/2004 | US20040203130 Subtilisin variants |
| 10/14/2004 | US20040203125 recombinant chimera produced using solid phase synthesis; for biosnesors/bioreactors, diagnostic and drugs |
| 10/14/2004 | US20040203118 Polynucleotides and polypeptides of the IFNalpha-14 gene |
| 10/14/2004 | US20040203116 IL-1 eta DNA and polypeptides |
| 10/14/2004 | US20040203111 UDP-N-acetylglucosamine: galactose-B1,3-N-acetylgalactosamine-a-R/ (GlcNAc to GalNAc) B1-6 N- acetylglucosaminyltransferase, C2GnT3 |
| 10/14/2004 | US20040203105 for drug screening emzyme inhibitors using genetically engineered animal models; for anticancer agents |
| 10/14/2004 | US20040203100 provides a family of antibodies that specifically bind the human cell surface glycosphingolipid GD2 for treating cancer by administering in vitro; genetic engineering |
| 10/14/2004 | US20040203098 Compounds and methods for modulating activation of NF-kappaB |
| 10/14/2004 | US20040203097 Kinases and phosphatases |
| 10/14/2004 | US20040203092 UDP-N-acetylglucosamine:galactose-beta1,3-N-acetylgalactosamine-alpha-R/ (GlcNAc to GalNAc) beta1-6 N-acetylglucosaminyltransferase, C2GnT3 |
| 10/14/2004 | US20040203084 protein antigens for producing neutralizing antibodies; biodrugs |
| 10/14/2004 | US20040203070 Method and means for detecting alcohol consumption |
| 10/14/2004 | US20040203063 Comprises nucleotide sequence coding tumor marker protein for use in diagnosis of prostate cancer |
| 10/14/2004 | US20040203039 Attenuated salmonella SP12 mutants as antigen carriers |
| 10/14/2004 | US20040203014 Neurotransmisson-associated proteins |
| 10/14/2004 | US20040203003 comprising isolating messenger RNA and performing reverse transcription polymerase chain reaction (PCR) and assessing the concentrations of the resulting amplicons; genetic engineering |
| 10/14/2004 | US20040202995 variable region polypeptides fused at their N-terminus to a bacterial signal sequence; providing an efficient way to select small antibody fragments that are labeled and that have high affinity to target ligand |
| 10/14/2004 | US20040202667 also use in the development of antimalarial drugs and antibodies directed against these Plasmodium proteins. |
| 10/14/2004 | US20040202666 Anti-cancer anthracycline drug-antibody conjugates |
| 10/14/2004 | US20040202665 agent, such as anticancer, antimetastasis, antileukemia, antidisease, antiadhesion, antithrombosis, antirestenosis, antiautoimmune, antiaggregation, antibacterial, antiviral, or antiinflammatory agents (preferably an anthracycline) and an antibody; the agent may be conjugated to the antibody |
| 10/14/2004 | US20040202664 Prevention of tumors with monoclonal antibodies against neu |
| 10/14/2004 | US20040202662 Humanised antibodies |
| 10/14/2004 | US20040202661 a peptide or derivative capable of binding to the IL-2 beta chain or the monoclonal antibodies produced by H2-8 hybridoma; induces SHC phosphorylation or induces the SHC/MAPK pathway |
| 10/14/2004 | US20040202660 orally administering an immunoglobulin to modulate serum IgG and/or TNF- Delta levels for treatment of autoimmune disorders, potentiation of vaccination protocols, and improvement of overall health and weight gain in animals, including humans. |
| 10/14/2004 | US20040202659 A polypeptide encoded by a nucleic acid that encodes a heavy chain, which is able to bind to GPIIb/IIIa, of a human antibody and comprising a CDR3 region; diagnosis, treatment or prevention of autoimmune thrombocytopenic purpura; modulating blood coagulation |
| 10/14/2004 | US20040202658 Therapy of autoimmune disease in a patient with an inadequate response to TNF-alpha inhibitor |
| 10/14/2004 | US20040202657 Humanized anti-CD3 specific antibodies |